Navigation Links
MiMedx Announces Its Support Of New CMS Packaging Payment Policy For Skin Substitutes
Date:11/29/2013

174; are 40 to 60 percent higher than the healing rates of our competitors' products.  Our strong clinical results and cost effective approach have enabled MiMedx to quickly gain market share. We believe the new reimbursement changes will enable us to continue that progress," added Bill Taylor, President and COO.

In the new system, CMS is dividing the skin substitutes into two groups for packaging purposes: high cost skin substitutes and low cost skin substitutes. Skin substitutes with an ASP amount above the weighted average of $32 per sq. cm. are classified in the high cost group and those at or below the weighted average per sq. cm. are classified in the low cost group.  The 2014 packaged rate for the low cost skin substitutes applied to DFUs and VLUs smaller than 100 sq. cm. is $409.41, and for the high cost skin substitutes is $1371.19.  As noted above, EpiFix® continues pass-through status for 2014, and it will be reimbursed on an ASP + 6% method.  It is worth noting that if EpiFix® were bundled in 2014, it would fall into the high cost packaged rate.

Taylor continued, "The size-appropriateness of our grafts, higher healing rates and fewer required applications to achieve wound closure have already enabled us to gain market share quickly. The DFU market for products such as EpiFix® is in excess of $2 billion annually.  Knowing that the VLU prevalence rate is nearly as high as the DFU rate, only with slightly larger wounds, we estimate the combined total DFU and VLU market for our EpiFix® products to be in excess of $4 billion annually.  To achieve our revenue guidance for 2014, we only need to capture 2.5% of that total possible DFU and VLU market, and that is excluding revenue from our other product lines."  

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and b
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MiMedx To Present At Canaccord Genuity Medical Technology And Diagnostics Forum
2. MiMedx Announces Record Third Quarter Results
3. MiMedx Reports On Meeting With FDA
4. MiMedx Responds To Misleading And Inaccurate Media Reports
5. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
6. MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
7. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
8. MiMedx Announces Record Second Quarter Results
9. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
10. MiMedx To Exceed High End Of Second Quarter Guidance
11. MiMedx to Ring NASDAQ Stock Market Opening Bell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... cell phones to cars and flashlights, batteries play ... technology companies constantly are seeking ways to improve ... time using a water-based solution, researchers at the ... more efficient nuclear battery that could be used ... source in automobiles and also in complicated applications ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
(Date:9/16/2014)... Sept. 16, 2014  Donald Fresne, President and CEO of ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl (European ... at Inserm, the French institute of health and medical research. ... at the Curie Institute, Orsay, France , ...
(Date:9/16/2014)... 16, 2014  The Council for Entrepreneurial Development ... in the country, today released a mid-year update ... It showed that in the first ... startups in the technology, life science, advanced ... from a variety of sources. Significant investment in technology ...
Breaking Biology Technology:BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... Annual Revenues Up, Net Loss Down, Cash Position Strong, as Pipeline ... ... (Nasdaq: EXEL ) today reported financial results for the full,year and ... $113.5 million, compared to $98.7 million in,2006. The increase in revenues for ...
... PALO ALTO, Calif., Feb. 14 Telik, Inc.,(Nasdaq: ... webcast will,be held on Thursday, February 21, 2008 at ... release earlier that day of the company,s,financial results for ... The conference call will be accessible via Telik,s ...
... Executives from Senexis,and O2H, both located in Cambridge, ... synthetic and computational chemistry services to the drug,discovery ... "We believe our collaboration with O2H leverages the ... search for new,therapeutics to treat ageing-related diseases by ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2
(Date:9/16/2014)... Sept. 16, 2014  Valencell, Inc., a leader in ... one of 18 "Showcase Companies" representing North ... annual CED Tech Venture Conference on September 16-17 th ... Center in Raleigh, North Carolina . ... a discussion during the "Digital Health Spotlight Sector" on ...
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... a common epilepsy drug to a morphine regimen can ... Moreover, the combination can reduce the dosage of the ... of pain researchers at Indiana University. , The result ... pain, a difficult-to-treat condition often felt in the arms ... "There is a huge unmet need for better treatments ...
Breaking Biology News(10 mins):Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... ago, the German Physical Society (DPG) has introduced the ... interdisciplinary applications of physics. The Prize, endowed with 5000 ... instrument to encourage research in this direction. This ... Max Planck Institute for Evolutionary Biology in Pln. He ...
... , New Rochelle, NY -- A novel method for ... help advance research on tissue engineering and regeneration, as ... Part C, Methods, a peer-reviewed journal from Mary Ann ... free online at the Tissue Engineering website ...
... proteins that actively pump a wealth of molecules across ... functions in humans. Genetic defects in ABC transporters can ... cystic fibrosis, and certain ABC transporters also cause resistance ... increased amounts of ABC transporters that pump chemotherapeutic substances ...
Cached Biology News:'Young Scientist Award for Socio- and Econophysics 2012' for Arne Traulsen 2
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Mycoplasma and virus tested...
Biology Products: